Menu
Back to Journals » OncoTargets and Therapy » Volume 3 » default
OncoTargets and Therapy
ISSN: 1178-6930
- View all (6405)
- Volume 16, 2023 (114)
- Volume 15, 2022 (191)
- Volume 14, 2021 (525)
- Volume 13, 2020 (1171)
- Volume 12, 2019 (1075)
- Volume 11, 2018 (882)
- Volume 10, 2017 (615)
- Volume 9, 2016 (802)
- Volume 8, 2015 (439)
- Volume 7, 2014 (253)
- Volume 6, 2013 (208)
- Volume 5, 2012 (54)
- Volume 4, 2011 (19)
- Volume 3, 2010 (22)
- Volume 2, 2009 (25)
- Volume 1, 2008 (10)
Archive: Volume 3, 2010
Survivin-T34A: molecular mechanism and therapeutic potential
Jonathan R Aspe, Nathan R Wall
OncoTargets and Therapy 2010, 3:247-254
Published Date: 6 December 2010
The spectrum of use of rituximab in chronic lymphocytic leukemia
Alessandra Tedeschi, Eleonora Vismara, Francesca Ricci, et al
OncoTargets and Therapy 2010, 3:227-246
Published Date: 26 November 2010
Pharmacological targeting of β-adrenergic receptor functions abrogates NF-κB signaling and MMP-9 secretion in medulloblastoma cells
Borhane Annabi, Eric Vaillancourt-Jean, Alexander G Weil, et al
OncoTargets and Therapy 2010, 3:219-226
Published Date: 15 November 2010
Post-surgical treatment of early-stage breast cancer with electronic brachytherapy: an intersociety, multicenter brachytherapy trial
Peter D Beitsch, Rakesh R Patel, John D Lorenzetti, et al
OncoTargets and Therapy 2010, 3:211-218
Published Date: 29 October 2010
Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics
Kimbach Tran Carpiuc, Gianantonio Rosti, Fausto Castagnetti, et al
OncoTargets and Therapy 2010, 3:205-210
Published Date: 11 October 2010
Use of electronic brachytherapy to deliver postsurgical adjuvant radiation therapy for endometrial cancer: a retrospective multicenter study
William C Dooley, John P Thropay, Gary J Schreiber, et al
OncoTargets and Therapy 2010, 3:197-203
Published Date: 21 September 2010
Profile of temsirolimus in the treatment of advanced renal cell carcinoma
Michael Staehler, Nicolas Haseke, Wael Khoder, et al
OncoTargets and Therapy 2010, 3:191-196
Published Date: 15 September 2010
The bevacizumab experience in advanced renal cell carcinoma
Lauren C Harshman, Sandy Srinivas
OncoTargets and Therapy 2010, 3:179-189
Published Date: 15 September 2010
Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
Nousheen Samad, Anas Younes
OncoTargets and Therapy 2010, 3:167-178
Published Date: 6 September 2010
Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
Steven E McCormack, Erica D Warlick
OncoTargets and Therapy 2010, 3:157-165
Published Date: 22 July 2010
New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
C Lance Cowey, Guru Sonpavde, Thomas E Hutson
OncoTargets and Therapy 2010, 3:147-155
Published Date: 20 September 2010
Temozolomide in malignant glioma
Gregor Dresemann
OncoTargets and Therapy 2010, 3:139-146
Published Date: 21 July 2010
Dynamic changes to survivin subcellular localization are initiated by DNA damage
Maritess Gay Asumen, Tochukwu V Ifeacho, Luke Cockerham, et al
OncoTargets and Therapy 2010, 3:129-137
Published Date: 1 July 2010
Current and emerging therapies for the treatment of pancreatic cancer
Rebecca A Moss, Clifton Lee
OncoTargets and Therapy 2010, 3:111-127
Published Date: 14 July 2010
A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency
Mariam Hammadi, Jacques-Olivier Pers, Christian Berthou, et al
OncoTargets and Therapy 2010, 3:99-109
Published Date: 15 June 2010
The dual kinase complex FAK-Src as a promising therapeutic target in cancer
Victoria Bolós, Joan Manuel Gasent, Sara López-Tarruella, et al
OncoTargets and Therapy 2010, 3:83-97
Published Date: 15 June 2010
Anti-angiogenesis therapies: their potential in cancer management
Andrew Eichholz, Shairoz Merchant, Andrew M Gaya
OncoTargets and Therapy 2010, 3:69-82
Published Date: 4 May 2010
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
Carmen Diana Schweighofer, Clemens-Martin Wendtner
OncoTargets and Therapy 2010, 3:53-67
Published Date: 30 March 2010
Update on options for treatment of metastatic castration-resistant prostate cancer
Prakash Vishnu, Winston W Tan
OncoTargets and Therapy 2010, 3:39-51
Published Date: 23 March 2010
New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab
Argirios Moustakas, Teri N Kreisl
OncoTargets and Therapy 2010, 3:27-38
Published Date: 11 March 2010
CTLA-4 blockade: therapeutic potential in cancer treatments
Ahmad A Tarhini, Fatima Iqbal
OncoTargets and Therapy 2010, 3:15-25
Published Date: 1 March 2010
An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
Jacqueline S Garcia, Nitin Jain, Lucy A Godley
OncoTargets and Therapy 2010, 3:1-13
Published Date: 25 February 2010